Pfizer (PFE) said Saturday that its investigational drug sasanlimab in combination with standard of care Bacillus Calmette-Guerin as induction and maintenance therapy in patients with high-risk non-muscle invasive bladder cancer met its primary endpoint of event-free survival in a phase 3 trial.
The trial showed a 32% reduction in the risk of disease-related events with the sasanlimab combination regimen as compared with the standard of care treatment alone, the pharmaceutircal giant said.
The probability of being event-free at 36 months was 82.1% with sasanlimab in combination with BCG and 74.8% with BCG alone, the company said.
Sasanlimab in combination with induction-only BCG failed to meet a secondary endpoint of prolongation of event-free survival compared with BCG alone as an induction and maintenance therapy, the company said.
Pfizer said it has shared study data with health authorities worldwide to support potential regulatory filings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.